Brind.

Innovent Biologics partnered with Spero Therapeutics Inc. to advance the development of IBI355.

Steady: 1 in the last 7 days Updated friday

The latest in this situation

  1. GSK out-licensed the commercialization rights for Spero Therapeutics' first drug.

How it started

2 reports, 1 independent, last reported Jul 14. The briefing below covers this first event.

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Innovent Biologics partnered with Spero Therapeutics Inc. to advance the development of IBI355.

Who's involved

What this event is mainly about

How it developed

Newest first. Tap a step to see who reported it.
  1. HCRx buys into Utebzi milestones and royalties, GSK grants exclusive license for Utebzi, and Spero in-licenses SP001 from Innovent Biologics.Sub-event
  2. Innovent Biologics announced a new partnership with Spero Therapeutics for IBI355 development.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
1 more outlet ran the same wire story